Skip to main content
SpringerLink
Log in

Neuroprotection of Retinal Ganglion Cells

  • Chapter
  • First Online:
The Glaucoma Book

  • 2536 Accesses

Abstract

Therapeutic efforts for treatment of glaucoma have focused on reduction of intraocular pressure as the main objective. In clinical practice, intraocular pressure (IOP) control has been expected to slow or arrest the glaucoma progression. However, clinicians have been confronted with significant glaucoma progression even when achieving control of intraocular pressure. In the Collaborative Normal-Tension Glaucoma Study, following medical or surgical treatment to achieve at least 30% reduction of intraocular pressure, 12% of patients experienced continued visual field loss secondary to optic nerve damage.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Anderson DR. Collaborative normal tension glaucoma study. Curr Opin Ophthalmol. 2003;14(2):86–90.

    Article  PubMed  Google Scholar 

  2. Weber AJ, Harman CD, Viswanathan S. Effects of optic nerve injury, glaucoma, and neuroprotection on the survival, structure, and function of ganglion cells in the mammalian retina. J Physiol. 2008;586(Pt 18):4393–4400.

    Article  CAS  PubMed  Google Scholar 

  3. Wax MB, Tezel G. Neurobiology of glaucomatous optic neuropathy: diverse cellular events in neurodegeneration and neuroprotection. Mol Neurobiol. 2002;26(1):45–55.

    Article  CAS  PubMed  Google Scholar 

  4. McKinnon SJ. Glaucoma, apoptosis, and neuroprotection. Curr Opin Ophthalmol. 1997;8(2):28–37.

    Article  CAS  PubMed  Google Scholar 

  5. Lipton SA. Retinal ganglion cells, glaucoma and neuroprotection. Prog Brain Res. 2001;131:712–718.

    CAS  PubMed  Google Scholar 

  6. Levin LA. Neuroprotection and regeneration in glaucoma. Ophthalmol Clin North Am 2005;18(4):585-596, vii.

    PubMed  Google Scholar 

  7. Levin LA. Mechanisms of optic neuropathy. Curr Opin Ophthalmol. 1997;8(6):9–15.

    Article  CAS  PubMed  Google Scholar 

  8. Farkas RH, Grosskreutz CL. Apoptosis, neuroprotection, and retinal ganglion cell death: an overview. Int Ophthalmol Clin. 2001;41(1):111–130.

    Article  CAS  PubMed  Google Scholar 

  9. Yoles E, Schwartz M. Potential neuroprotective therapy for glaucomatous optic neuropathy. Surv Ophthalmol. 1998;42(4):367–372.

    Article  CAS  PubMed  Google Scholar 

  10. Whitcup SM. Clinical trials in neuroprotection. Prog Brain Res. 2008;173:323–335.

    Article  PubMed  Google Scholar 

  11. Weinreb RN. Glaucoma neuroprotection: What is it? Why is it needed? Can J Ophthalmol. 2007;42(3):396–398.

    Article  PubMed  Google Scholar 

  12. Wein FB, Levin LA. Current understanding of neuroprotection in glaucoma. Curr Opin Ophthalmol. 2002;13(2):61–67.

    Article  PubMed  Google Scholar 

  13. Osborne NN, Chidlow G, Nash MS, Wood JP. The potential of neuroprotection in glaucoma treatment. Curr Opin Ophthalmol. 1999;10(2):82–92.

    Article  CAS  PubMed  Google Scholar 

  14. Osborne NN, Chidlow G, Layton CJ, Wood JP, Casson RJ, Melena J. Optic nerve and neuroprotection strategies. Eye. 2004;18(11):1075–1084.

    Article  CAS  PubMed  Google Scholar 

  15. Dreyer EB. The potential for neuroprotection in glaucoma. Ophthalmol Clin North Am. 1997;10:365–376.

    Google Scholar 

  16. Weinreb RN. Neuroprotection-possibilities in perspective. Surv Ophthalmol. 2001;45(Suppl 3):S241-S242.

    Article  PubMed  Google Scholar 

  17. Osborne NN. Pathogenesis of ganglion “cell death” in glaucoma and neuroprotection: focus on ganglion cell axonal mitochondria. Prog Brain Res. 2008;173:339–352.

    Article  CAS  PubMed  Google Scholar 

  18. Nickells RW. Retinal ganglion cell death in glaucoma: the how, the why, and the maybe. J Glaucoma. 1996;5(5):345–356.

    Article  CAS  PubMed  Google Scholar 

  19. Kalapesi FB, Coroneo MT, Hill MA. Human ganglion cells express the alpha-2 adrenergic receptor: relevance to neuroprotection. Br J Ophthalmol. 2005;89(6):758–763.

    Article  CAS  PubMed  Google Scholar 

  20. Rosa RH Jr, Hein TW, Yuan Z, et al. Brimonidine evokes heterogeneous vasomotor response of retinal arterioles: diminished nitric oxide-mediated vasodilation when size goes small. Am J Physiol Heart Circ Physiol. 2006;291(1):H231-H238.

    Article  CAS  PubMed  Google Scholar 

  21. Neufeld AH, Hernandez MR, Gonzalez M. Nitric oxide synthase in the human glaucomatous optic nerve head. Arch Ophthalmol. 1997;115(4):497–503.

    CAS  PubMed  Google Scholar 

  22. Harris A, Ciulla TA, Kagemann L, Zarfati D, Martin B. Vasoprotection as neuroprotection for the optic nerve. Eye 2000;14(Pt 3B):473–475.

    PubMed  Google Scholar 

  23. Schwartz M, London A. Glaucoma as a neuropathy amenable to neuroprotection and immune manipulation. Prog Brain Res. 2008;173:375–384.

    Article  PubMed  Google Scholar 

  24. Schwartz M. Harnessing the immune system for neuroprotection: therapeutic vaccines for acute and chronic neurodegenerative disorders. Cell Mol Neurobiol. 2001;21(6):617–627.

    Article  CAS  PubMed  Google Scholar 

  25. Schwartz M. Physiological approaches to neuroprotection. boosting of protective autoimmunity. Surv Ophthalmol. 2001;45(Suppl 3):S256-S260; discussion S273-S276.

    Article  PubMed  Google Scholar 

  26. Bakalash S, Kipnis J, Yoles E, Schwartz M. Resistance of retinal ganglion cells to an increase in intraocular pressure is immune-dependent. Invest Ophthalmol Vis Sci. 2002;43(8):2648–2653.

    PubMed  Google Scholar 

  27. Bakalash S, Kessler A, Mizrahi T, Nussenblatt R, Schwartz M. Antigenic specificity of immunoprotective therapeutic vaccination for glaucoma. Invest Ophthalmol Vis Sci. 2003;44(8):3374–3381.

    Article  PubMed  Google Scholar 

  28. Neufeld AH, Liu B. Glaucomatous optic neuropathy: when glia misbehave. Neuroscientist. 2003;9(6):485–495.

    Article  CAS  PubMed  Google Scholar 

  29. Osborne NN, Ugarte M, Chao M, et al. Neuroprotection in relation to retinal ischemia and relevance to glaucoma. Surv Ophthalmol. 1999;43(Suppl 1):S102-S128.

    Article  PubMed  Google Scholar 

  30. Cordeiro MF, Erskine L. Back to basics - ephrins, axonal guidance, neuroprotection and glaucoma. Br J Ophthalmol. 2007;91(9):1106.

    Article  PubMed  Google Scholar 

  31. Tezel G. TNF-alpha signaling in glaucomatous neurodegeneration. Prog Brain Res. 2008;173:409–421.

    Article  CAS  PubMed  Google Scholar 

  32. Lipton SA. Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation. Curr Drug Targets. 2007;8(5):621–632.

    Article  CAS  PubMed  Google Scholar 

  33. Dreyer EB. A proposed role for excitotoxicity in glaucoma. J Glaucoma. 1998;7(1):62–67.

    Article  CAS  PubMed  Google Scholar 

  34. Dong CJ, Guo Y, Agey P, Wheeler L, Hare WA. Alpha2 adrenergic modulation of NMDA receptor function as a major mechanism of RGC protection in experimental glaucoma and retinal excitotoxicity. Invest Ophthalmol Vis Sci. 2008;49(10):4515–4522.

    Article  PubMed  Google Scholar 

  35. Osborne NN. Recent clinical findings with memantine should not mean that the idea of neuroprotection in glaucoma is abandoned. Acta Ophthalmol 2008.

    Google Scholar 

  36. Neufeld AH, Sawada A, Becker B. Inhibition of nitric-oxide synthase 2 by aminoguanidine provides neuroprotection of retinal ganglion cells in a rat model of chronic glaucoma. Proc Natl Acad Sci U S A. 1999;96(17):9944–9948.

    Article  CAS  PubMed  Google Scholar 

  37. Schwartz M. Neuroprotection as a treatment for glaucoma: pharmacological and immunological approaches. Eur J Ophthalmol. 2003;13(Suppl 3):S27-S31.

    PubMed  Google Scholar 

  38. Kitaoka Y, Kumai T. Modulation of retinal dopaminergic cells by nitric oxide. A protective effect on NMDA-induced retinal injury. In Vivo. 2004;18(3):311–315.

    CAS  PubMed  Google Scholar 

  39. Wheeler L, WoldeMussie E, Lai R. Role of alpha-2 agonists in neuroprotection. Surv Ophthalmol. 2003;48(Suppl 1):S47-S51.

    Article  PubMed  Google Scholar 

  40. Wheeler LA, Woldemussie E. Alpha-2 adrenergic receptor agonists are neuroprotective in experimental models of glaucoma. Eur J Ophthalmol. 2001;11(Suppl 2):S30-S35.

    PubMed  Google Scholar 

  41. Chidlow G, Wood JP, Casson RJ. Pharmacological neuroprotection for glaucoma. Drugs. 2007;67(5):725–759.

    Article  CAS  PubMed  Google Scholar 

  42. Tsai JC, Song BJ, Wu L, Forbes M. Erythropoietin: a candidate neuroprotective agent in the treatment of glaucoma. J Glaucoma. 2007;16(6):567–571.

    Article  PubMed  Google Scholar 

  43. Zhong L, Bradley J, Schubert W, et al. Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice. Invest Ophthalmol Vis Sci. 2007;48(3):1212–1218.

    Article  PubMed  Google Scholar 

  44. Weishaupt JH, Rohde G, Polking E, Siren AL, Ehrenreich H, Bahr M. Effect of erythropoietin axotomy-induced apoptosis in rat retinal ganglion cells. Invest Ophthalmol Vis Sci. 2004;45(5):1514–1522.

    Article  PubMed  Google Scholar 

  45. Kumar DM, Simpkins JW, Agarwal N. Estrogens and neuroprotection in retinal diseases. Mol Vis. 2008;14:1480–1486.

    CAS  PubMed  Google Scholar 

  46. Zhou X, Li F, Ge J, et al. Retinal ganglion cell protection by 17-beta-estradiol in a mouse model of inherited glaucoma. Dev Neurobiol. 2007;67(5):603–616.

    Article  CAS  PubMed  Google Scholar 

  47. Schori H, Kipnis J, Yoles E, et al. Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma. Proc Natl Acad Sci U S A. 2001;98(6):3398–3403.

    Article  CAS  PubMed  Google Scholar 

  48. Lagreze WA, Muller-Velten R, Feuerstein TJ. The neuroprotective properties of gabapentin-lactam. Graefes Arch Clin Exp Ophthalmol. 2001;239(11):845–849.

    Article  CAS  PubMed  Google Scholar 

  49. Yu MS, Lai CS, Ho YS, et al. Characterization of the effects of anti-aging medicine Fructus lycii on beta-amyloid peptide neurotoxicity. Int J Mol Med. 2007;20(2):261–268.

    CAS  PubMed  Google Scholar 

  50. Chung HS, Harris A, Kristinsson JK, Ciulla TA, Kagemann C, Ritch R. Ginkgo biloba extract increases ocular blood flow velocity. J Ocul Pharmacol Ther. 1999;15(3):233–240.

    Article  CAS  PubMed  Google Scholar 

  51. Zhang B, Rusciano D, Osborne NN. Orally administered epigallocatechin gallate attenuates retinal neuronal death in vivo and light-induced apoptosis in vitro. Brain Res. 2008;1198:141–152.

    Article  CAS  PubMed  Google Scholar 

  52. Bull ND, Johnson TV, Martin KR. Stem cells for neuroprotection in glaucoma. Prog Brain Res. 2008;173:511–519.

    Article  CAS  PubMed  Google Scholar 

  53. Schober MS, Chidlow G, Wood JP, Casson RJ. Bioenergetic-based neuroprotection and glaucoma. Clin Experiment Ophthalmol. 2008;36(4):377–385.

    Article  PubMed  Google Scholar 

  54. Guo L, Cordeiro MF. Assessment of neuroprotection in the retina with DARC. Prog Brain Res. 2008;173:437–450.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hamilton Eye Institute, University of Tennessee Health Science Center, Memphis, TN, USA

    Alvaro P. C. Lupinacci MD

  2. Specialty Eyecare Centre, Bellevue, WA, USA

    Howard Barnebey MD

  3. Department of Ophthalmology, University of Virginia School of Medicine, Charlottesville, VA, USA

    Peter A. Netland MD, PhD

Authors
  1. Alvaro P. C. Lupinacci MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Howard Barnebey MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter A. Netland MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. 2889 10th Avenue, N., Palm Springs, 33461, USA

    Paul N. Schacknow

  2. Casey Eye Institute, Dept. Ophthalmology, Oregon Health & Sciences University, SW. Terwilliger Blvd. 3375, Portland, 97201-4197, USA

    John R. Samples

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Lupinacci, A.P.C., Barnebey, H., Netland, P.A. (2010). Neuroprotection of Retinal Ganglion Cells. In: Schacknow, P., Samples, J. (eds) The Glaucoma Book. Springer, New York, NY. https://doi.org/10.1007/978-0-387-76700-0_54

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-76700-0_54

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-76699-7

  • Online ISBN: 978-0-387-76700-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation